Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05194735	TitlePhase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors	Phase Phase 1	Date Added 2022-01-18	Location Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product	Tags MSS/ MMRp
NCT ID NCT05722327	TitlePhase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	Phase Phase 1	Date Added 2023-02-10	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, Irinotecan, MRTX849	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03772561	TitlePhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies	Phase Phase 1	Date Added 2018-12-11	Location Singapore	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs AZD5363+Olaparib+Durvalumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06105021	TitlePhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor	Phase Phase 1, Phase 2	Date Added 2023-10-27	Location California, United States Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs AFNT-211	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06302062	TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors	Phase Phase 1	Date Added 2024-03-08	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04793958	TitlePhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)	Phase Phase 3	Date Added 2021-03-11	Location Alabama, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Brazil Canada China Colombia Czechia Denmark Finland France Germany Greece Hong Kong Ireland Italy Korea, Republic of Malaysia Mexico Netherlands Poland Portugal Puerto Rico Romania Singapore Spain Taiwan Thailand Ukraine United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06589440	TitlePhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	Phase Phase 2	Date Added 2024-09-19	Location New Jersey, United States Texas, United States Washington, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Balstilimab, Botensilimab	Tags MSS/ MMRp
NCT ID NCT05480306	TitlePhase 2 Study of DKN-01 in Colorectal Cancer	Phase Phase 2	Date Added 2022-07-29	Location Arizona, United States California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States Germany Korea, Republic of	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bevacizumab, DKN-01, FOLFIRI, FOLFOX	Tags MSS/ MMRp
NCT ID NCT06039202	TitlePhase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2023-09-15	Location	Prior IO Allowed Yes	CRC-directed Yes	Status Not yet recruiting	Drugs CA102N, TAS-102	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04046445	TitlePhase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer	Phase Phase 1	Date Added 2019-08-06	Location Arizona, United States California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States Belgium Germany Switzerland	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs ATP128, BI 754091, VSV-GP128	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 91 to 100 of 299 entries